OrsoBio is developing novel approaches to treat patients with severe metabolic disorders, including obesity, diabetes, severe dyslipidemias, MASH, and more.
OrsoBio’s therapies target fundamental pathways of energy metabolism, and our team of physicians and scientists draw on decades of drug development experience.
The OrsoBio team is a group of forward-thinking scientists and proven biotech leaders who are deeply committed to advancing new therapies to help patients with severe metabolic disorders. Our mission is to redefine the treatment of these disorders by addressing their root cause.
Focusing on severe metabolic disorders with major morbidity and mortality
Targeting fundamental aspects of metabolism with first-in-class therapies to restore energy homeostasis and improve clinical outcomes
Dedicated MDs and PhDs with decades of clinical and drug development experience
OrsoBio team members collaborated with Professor Takebe in his pioneering study in Cell on the first use of en masse human liver organoids to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.
